IDSA GUIDELINES Bundle (free trial)

HAP / VAP

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/739791

Contents of this Issue

Navigation

Page 2 of 11

3 Diagnosis Microbiologic Methods Î ATS and IDSA suggest noninvasive sampling with semiquantitative cultures to diagnose VAP, rather than invasive sampling with quantitative cultures and rather than noninvasive sampling with quantitative cultures (W-L). Î Noninvasive sampling with semiquantitative cultures is the preferred methodology to diagnose VAP. However, the panel recognizes that invasive quantitative cultures will occasionally be performed by some clinicians. For patients with suspected VAP whose invasive quantitative culture results are below the diagnostic threshold for VAP, ATS and IDSA suggest that antibiotics be withheld rather than continued (W-VL). Î ATS and IDSA suggest that patients with suspected HAP (non-VAP) be treated according to the results of microbiologic studies performed on respiratory samples obtained noninvasively, rather than being treated empirically (W-VL). Biomarkers Î For patients with suspected HAP/VAP, ATS and IDSA recommend using clinical criteria alone, rather than using serum procalcitonin plus clinical criteria, to decide whether or not to initiate antibiotic therapy (S-M). Î For patients with suspected HAP/VAP, ATS and IDSA recommend using clinical criteria alone, rather than using bronchoalveolar fluid sTREM-1 plus clinical criteria, to decide whether or not to initiate antibiotic therapy (S-M). Î For patients with suspected HAP/VAP, ATS and IDSA recommend using clinical criteria alone rather than using C-Reactive Protein (CRP) plus clinical criteria, to decide whether or not to initiate antibiotic therapy (W-L). Î For patients with suspected HAP/VAP, ATS and IDSA suggest using clinical criteria alone, rather than using Modified Clinical Pulmonary Infection Score (CPIS) plus clinical criteria, to decide whether or not to initiate antibiotic therapy (W-L). S, strong ; W, weak strength of recommendation H, high; M, moderate; L, low; VL, very low quality of evidence

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - HAP / VAP